PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 15199869

Lessons from two "triple nuke" failures (new training module).

View original source ↗Export metadata ↓

Abstract

A CME (continuing medical education) module for physicians explains the problem with two antiretroviral regimens that failed last year. Several possible causes for the failure had been proposed. Now it appears that the problem was too low a genetic barrier to HIV developing certain resistance mutations.

Explore related subjects

Drug Therapy, CombinationHIV InfectionsHumansReverse Transcriptase InhibitorsNewspaper ArticleJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

2004-03-26. Lessons from two "triple nuke" failures (new training module).. https://pubmed.ncbi.nlm.nih.gov/15199869/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living donor liver transplant recipients with hepatitis C.

Double-filtration plasmapheresis (DFPP) selectively removes high molecular weight substances including hepatitis C virus (HCV). Four live donor liver transplantation (LDLT) recipients with HCV received combination therapy with low-dose interferon (IFN) and ribavirin with DFPP. Three patients underwent this therapy for prophylaxis of HCV recurrence, and one for treating fibrosing cholestatic hepatitis (FCH). The combination therapy and DFPP decreased HCV RNA levels to 8.2% +/- 2.9% and 0.7% +/- 0.5% by the 5th and 30th day of treatment, respectively. Three patients who underwent DFPP for prophylaxis showed no evidence of HCV recurrence for >1 year after treatment. The patient whose graft showed FCH, recovered dramatically after the DFPP treatment. DFPP appeared to be effective in reducing HCV viremia and preventing HCV recurrence in patients with high HCV RNA levels after LDLT. Moreover, it may become a rescue therapy for FCH in a liver transplant recipient with hepatitis C.

Drug Therapy, Combination↗